: Secukinumab was shown to be effective in treating moderate-to-severe plaque psoriasis in adults and pediatric patients ≥6 years. : A literature review was conducted to identify studies published in the preceding 5 years assessing the effectiveness and/or survival (safety in the second instance) associated with secukinumab treatment for moderate-to-severe plaque psoriasis with/without psoriatic arthritis (PsA) in real-world clinical practice in Spain. : 11 references were included, corresponding to seven studies (six retrospective and one prospective) (n = 1050). Baseline characteristics were mean age 46.5-53.0 years; 28.7-55.0% women; 30.0-53.1% patients with PsA; 27.9-47.4% naïve to biologic treatments; mean Psoriasis Area and Severity Index (PASI) score 12.5 (standard deviation [SD]: 6.9)-18.1 (SD: 10.3). PASI 90 response rates were 54-65% at Week 24 and 46-63% at Week 52; 43-47% of patients showed PASI ≤ 1 at Week 12 and 47-56% at Week 52. Treatment persistence at Week 52 was 72-89%, being 74.5% in the larger cohort series (n = 384) at 2 years. Adverse-event-related treatment discontinuation was rare. : Secukinumab demonstrated long-term safety and efficacy in treating adult patients with moderate-to-severe plaque psoriasis in actual clinical practice, with survival rates of up to two years and consistent efficacy in Spain.